Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05069675
Other study ID # 69/2021/PO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 12, 2021
Est. completion date January 2023

Study information

Verified date May 2022
Source University of Catania
Contact Antonio Longo, MD, PhD
Phone +393460131548
Email antlongo@unict.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the incidence of cystoid macular edema in eyes with primary rhegmatogenous retinal detachment successfully treated with vitrectomy with gas tamponade, and to evaluate the clinical variables associated with its development.


Description:

this is an observational, retrospective, multicentre study. The study is based on the retrospective collection of clinical data from patients undergoing gas tamponade vitrectomy for rhegmatogenous retinal detachment. The collection of such data by the investigators will take place at each participating center anonymously. demographics, systemic, and preoperative, intraoperative and post-operative data will be collected The sample size was calculated to obtain approximately 200 patients with cystoid macular edema. Since cystoid macular edema has been detected in 13% of patients after retinal detachment gas vitrectomy, and assuming that this event can occur between 10% and 15% of cases, the study will include at least 2000 cases.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date January 2023
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - primary rhegmatogenous retinal detachment treated with vitrectomy with gas tamponade; - follow-up of 3 months or more; - age > 18 years ; - no previous eye surgery, except cataract surgery performed at least 6 months after hospitalization for retinal detachment; - anatomical success, i.e. retinal re-attachment, after a single gas vitrectomy; - no other eye surgery during follow-up; - availability of optical coherence tomography (OCT) imaging Exclusion Criteria: - history of other eye diseases (glaucoma, age-related macular degeneration, uveitis, diabetic retinopathy, maculopathy); - macular hole; - recurrent retinal detachment; - use of silicone oil is used as a tamponading agent

Study Design


Intervention

Procedure:
vitrectomy
vitrectomy with gas tamponade

Locations

Country Name City State
Italy Eye Clinic, University of Bari Bari
Italy Eye Clinic, Humanitas University Bergamo
Italy Eye Clinic, Azienda Policlinico San Marco Catania
Italy Eye Clinic, University of Palermo Palermo
Italy Eye Clinic, University of Perugia Perugia
Italy Eye Clinic University of Turin Turin

Sponsors (1)

Lead Sponsor Collaborator
University of Catania

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Banker TP, Reilly GS, Jalaj S, Weichel ED. Epiretinal membrane and cystoid macular edema after retinal detachment repair with small-gauge pars plana vitrectomy. Eur J Ophthalmol. 2015 Nov-Dec;25(6):565-70. doi: 10.5301/ejo.5000609. Epub 2015 Apr 15. — View Citation

Chatziralli I, Theodossiadis G, Dimitriou E, Kazantzis D, Theodossiadis P. Macular Edema after Successful Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: Factors Affecting Edema Development and Considerations for Treatment. Ocul Immunol Inflamm. 2021 Jan 2;29(1):187-192. doi: 10.1080/09273948.2019.1652330. Epub 2019 Oct 2. — View Citation

Joseph DP, Ryan EH, Ryan CM, Forbes NJK, Wagley S, Yonekawa Y, Mittra RA, Parke DW, Emerson GG, Shah GK, Blinder KJ, Capone A, Williams GA, Eliott D, Gupta OP, Hsu J, Regillo CD. Primary Retinal Detachment Outcomes Study: Pseudophakic Retinal Detachment Outcomes: Primary Retinal Detachment Outcomes Study Report Number 3. Ophthalmology. 2020 Nov;127(11):1507-1514. doi: 10.1016/j.ophtha.2020.05.005. Epub 2020 May 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of cystoid macular edema cystoid macular edema assessed by OCT (central subfield thickness >310 micron, with presence of intraretinal cystic areas of low reflectivity in OPL) visual acuity from 1 month up to 6 months after surgery
Secondary factors related to development of macular edema demographics, systemic and ocular parameters from 1 month up to 6 months after surgery
See also
  Status Clinical Trial Phase
Completed NCT00508040 - Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a Phase 2
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT03025945 - Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo N/A
Completed NCT01978015 - Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Phase 4
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Withdrawn NCT02598869 - Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Phase 4
Terminated NCT04527523 - Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
Completed NCT02294656 - Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Phase 1
Not yet recruiting NCT04856670 - Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS
Completed NCT02609165 - Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema Phase 2
Withdrawn NCT00438243 - Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema. Phase 2
Completed NCT00464581 - Lucentis for Treatment of Macular Edema N/A
Active, not recruiting NCT03465124 - Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery N/A
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Completed NCT00790803 - Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema N/A
Recruiting NCT04225611 - Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema Phase 1/Phase 2
Completed NCT05832996 - Cool vs Room-temperature Artificial Tears Phase 4
Completed NCT05615805 - The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections N/A
Completed NCT00494494 - Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Phase 4
Terminated NCT00346983 - Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics Phase 1/Phase 2